August 28th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
AstraZeneca Restructures Vaccines R&D and Operations
July 24th 2012MedImmune, the global biologics arm of AstraZeneca, announced that it is restructuring its infectious disease and vaccines R&D and operations. This will result in the closure of MedImmune's sites in Mountain View and Santa Clara, California.